



# LKT Laboratories, Inc.

## Lapatinib free base

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

### Product Information

Product ID L0362  
CAS No. 231277-92-2  
Chemical Name Lapatinib


Synonym GSK572016, GW572016

Formula  $C_{29}H_{26}ClFN_4O_4S$   
Formula Wt. 581.06  
Melting Point  
Purity  $\geq 99\%$   
Solubility

Store Temp  $-20^{\circ}C$

Ship Temp Ambient

Description Lapatinib is an inhibitor of EGFR/HER2 (ErbB2) that is currently in clinical trials as a co-administered treatment with other chemotherapeutics. Lapatinib exhibits anticancer chemotherapeutic benefit, inducing apoptosis in breast cancer cells. This compound also downregulates expression of thymidylate synthase in vitro.



### Pricing and Availability

*Bulk quantities available upon request*

Product ID	Size	List Price
L0362	5 mg	\$57.80
L0362	25 mg	\$105.00
L0362	100 mg	\$236.30

References Janni W, Sarosiek T, Karaszewska B, et al. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2014 Jan 9. [Epub ahead of print]. PMID: 24402830.

Kostyal D, Welt RS, Danko J, et al. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. Med Oncol. 2012 Sep;29(3):1486-94. PMID: 21769502.

Kim HP, Yoon YK, Kim JW, et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One. 2009 Jun 16;4(6):e5933. PMID: 19529774.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.